Company Analysis REGENXBIO
1. Summary
Advantages
- Price (14.2 $) is less than fair price (15.29 $)
- The stock's return over the last year (-11.75%) is higher than the sector average (-29.77%).
Disadvantages
- Dividends (0%) are below the sector average (0.5491%).
- Current debt level 15.56% has increased over 5 years from 1.08%.
- The company's current efficiency (ROE=-84.52%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| REGENXBIO | Healthcare | Index | |
|---|---|---|---|
| 7 days | 46.1% | -16.4% | 1.7% |
| 90 days | 10.3% | -46.1% | 6.1% |
| 1 year | -11.7% | -29.8% | 33.5% |
RGNX vs Sector: REGENXBIO has outperformed the "Healthcare" sector by 18.02% over the past year.
RGNX vs Market: REGENXBIO has significantly underperformed the market by -45.27% over the past year.
Stable price: RGNX is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: RGNX with weekly volatility of -0.2259% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (14.2 $) is lower than the fair price (15.29 $).
Price not significantly lower than the fair price: The current price (14.2 $) is slightly lower than the fair price by 7.7%.
4.2. P/E
P/E vs Sector: The company's P/E (12.54) is lower than that of the sector as a whole (48.77).
P/E vs Market: The company's P/E (12.54) is lower than that of the market as a whole (48.05).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.61) is lower than that of the sector as a whole (4.82).
P/BV vs Market: The company's P/BV (2.61) is lower than that of the market as a whole (3.1).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (9.02) is lower than that of the sector as a whole (33.76).
P/S vs Market: The company's P/S indicator (9.02) is lower than that of the market as a whole (10.14).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-3.47) is higher than that of the sector as a whole (-22.12).
EV/Ebitda vs Market: The company's EV/Ebitda (-3.47) is lower than that of the market as a whole (19.1).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 35.65% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (35.65%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-9.16%).
5.4. ROE
ROE vs Sector: The company's ROE (-84.52%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (-84.52%) is lower than that of the market as a whole (10.87%).
5.5. ROA
ROA vs Sector: The company's ROA (-45.91%) is lower than that of the sector as a whole (0.3359%).
ROA vs Market: The company's ROA (-45.91%) is lower than that of the market as a whole (6.5%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (17.5%) is higher than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (17.5%) is higher than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5491%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 05.03.2024 | PAKOLA STEVE Chief Medical Officer |
Sale | 28.36 | 365 220 | 12 878 |
| 05.03.2024 | PAKOLA STEVE Chief Medical Officer |
Purchase | 22.25 | 286 536 | 12 878 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
